WP7 - Translation of NGS data on industry applications

The main objectives of the WP7 are devoted to use the collected NGS findings to select the most promising genomic alterations with a potential role as diagnostic and prognostic biomarkers for acute and chronic leukemias and thus useful for patients stratification according to a personalized medicine approach.

In particular, WP7 is focused on the development of new “leukemia diagnostic panels” for specific mutations, genomic/transcript alterations and miRNA biomarkers, which will help a fast and comprehensive screening of diagnostic leukemia samples, as well as of the analysis of risk-assessment and prediction of therapy-failure.

WP7 will finally lead to the inclusion of relevant genomic alterations in novel clinical trials.